What is NRSN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NRSN?

P/E (TTM) is n/a and 52-week range is $2.87 to $26.64 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NRSN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NRSN?

The company profile lists net income (TTM) near $-381M, EPS (TTM) near $-10.79 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Neurosense Therapeutics Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Herzliya, IL, 35.4M shares outstanding, ISIN IL0011809592 when available from company profile and filing metadata.

Free AI scores & summaries library

Neurosense Therapeutics Ltd

$NRSN

Health Care · Biotechnology

IR Run Scenarios

$2.69

-12.38%

Free AI scores & summaries library

Neurosense Therapeutics Ltd

$NRSN

Health Care · Biotechnology

IR Run Scenarios

$2.69

-12.38%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Employees

17

Website

www.neurosense-tx.com/

IPO

2021-12-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

IL0011809592

Headquarters

Herzliya, IL

Shares outstanding

35.4M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

0.86%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Employees

17

Website

www.neurosense-tx.com/

IPO

2021-12-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)